Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EBIT (2017 - 2025)

Cue Biopharma (CUE) has disclosed EBIT for 9 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 1.19% to $23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.5 million through Dec 2025, up 35.83% year-over-year, with the annual reading at -$5.5 million for FY2025, 35.83% up from the prior year.
  • EBIT hit $23.0 million in Q4 2025 for Cue Biopharma, up from -$7.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $23.3 million in Q4 2024 to a low of -$14.9 million in Q4 2022.
  • Historically, EBIT has averaged -$8.2 million across 5 years, with a median of -$11.9 million in 2023.
  • Biggest five-year swings in EBIT: tumbled 88.34% in 2022 and later soared 268.64% in 2024.
  • Year by year, EBIT stood at -$7.9 million in 2021, then crashed by 88.34% to -$14.9 million in 2022, then grew by 6.96% to -$13.8 million in 2023, then skyrocketed by 268.64% to $23.3 million in 2024, then decreased by 1.19% to $23.0 million in 2025.
  • Business Quant data shows EBIT for CUE at $23.0 million in Q4 2025, -$7.6 million in Q3 2025, and -$8.6 million in Q2 2025.